In vitro and in vivo enhancement of ganciclovir-mediated bystander cytotoxicity with gemcitabine

Molecular Therapy

Volumn 12, Issue 6, 2005, Pages 1064-1071

  Boucher, Paul D ^a   Shewach, Donna S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Bystander effect; Ganciclovir; Gemcitabine; HSV TK; Suicide gene therapy

Indexed keywords

BETA GALACTOSIDASE; DEOXYGUANOSINE TRIPHOSPHATE; DNA; GANCICLOVIR; GEMCITABINE; THYMIDINE KINASE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BYSTANDER EFFECT; CANCER INHIBITION; CARCINOMA CELL; CELL KILLING; CELL LEVEL; COCULTURE; COLON CARCINOMA; CONTROLLED STUDY; DATA ANALYSIS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL CULTURE; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA; DRUG SYNERGISM; FEMALE; GANCICLOVIR; GENE THERAPY; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; SIMPLEXVIRUS; THYMIDINE KINASE;

ANIMALIA; MURINAE; SIMPLEXVIRUS;

EID: 28444471183     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.07.643     Document Type: Article

References (48)

1. F.L. Moolten Drug sensitivity ("suicide") genes for selective cancer chemotherapy Cancer Gene Ther. 1 1994 279-287
2. J. Balzarini C. Bohman and E. DeClercq Differential metabolism of cytostatic of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2 J. Biol. Chem. 269 1993 6332-6337
3. O. Greco and G.U. Dachs Gene directed enzyme/prodrug therapy for cancer: historical appraisal and future prospectives J. Cell. Physiol. 187 2001 22-36
4. L.Z. Rubsam B.L. Davidson and D.S. Shewach Superior cytotoxicity with ganciclovir compared with acyclovir and 1-β-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: A novel paradigm for cell killing Cancer Res. 58 1998 3873-3882
5. K.K. Biron et al. Metabolic activation of the nucleoside analog 9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}guanine in human diploid fibroblasts infected with human cytomegalovirus Proc. Natl. Acad. Sci. USA 82 1985 2473-2477
6. J.E. Reardon Herpes simplex virus type 1 and human DNA polymerase interactions with 2′-deoxyguanosine 5′-triphosphate analogues J. Biol. Chem. 264 1989 19039-19044
7. M.T. Tomicic R. Thust and B. Kaina Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: Critical role of DNA breaks, Bcl-2 decline and caspase-9 activation Oncogene 21 2002 2141-2153
8. Z.D. Ezzeddine et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene New Biol. 3 1991 608-614
9. J.M. DiMaio et al. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo Surgery 116 1994 205-213
10. M. Caruso et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene Proc. Natl. Acad. Sci. USA 90 1993 7024-7028
11. Z. Ram et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats Cancer Res. 53 1993 83-88
12. R.G. Vile and I.R. Hart Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA Cancer Res. 53 1993 3860-3864
13. B.W. O'Malley Jr. S.-H. Chen M.R. Schwartz and S.L.C. Woo Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model Cancer Res. 55 1995 1080-1085
14. K. Yoshida et al. Retrovirally transmitted gene therapy for gastric carcinoma using herpes simplex virus thymidine kinase gene Cancer 75 1995 1467-1471
15. J.A. Roth and R.J. Cristiano Gene therapy for cancer: What have we done and where are we going? J. Natl. Cancer Inst. 89 1997 21-39
16. M.R. Dyer and P.L. Herrling Progress and potential for gene-based medicines Mol. Ther. 1 2000 213-224
17. N. Shand et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir Hum. Gene Ther. 10 1999 2325-2335
18. A. Immonen et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomized, control study Mol. Ther. 10 2004 967-972
19. S.O. Freytag et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for treatment of locally recurrent prostate cancer Cancer Res. 62 2002 4968-4976
20. S.O. Freytag et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer Cancer Res. 63 2003 7497-7506
21. S.M. Freeman et al. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified Cancer Res. 53 1993 5274-5283
22. C. Denning and J.D. Pitts Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes Hum. Gene Ther. 8 1997 1825-1835
23. P.D. Boucher R.J. Ruch and D.S. Shewach Differential ganciclovir-mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase Hum. Gene Ther. 9 1998 801-814
24. L.Z. Rubsam et al. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells Cancer Res. 59 1999 669-675
25. W.L. Bi L.M. Parysek R. Warnick and P.J. Stambrook In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy Hum. Gene Ther. 4 1993 725-731
26. R.L. Touraine et al. The bystander effect in the HSVtk/ganciclovir system and its relation to gap junctional communication Gene Ther. 5 1998 1705-1711
27. H. Ishii-Morita et al. Mechanism of "bystander effect" killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment Gene Ther. 4 1997 244-251
28. P.D. Boucher L.J. Ostruska and D.S. Shewach Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir-mediated cytotoxicity by hydroxyurea Cancer Res. 60 2000 1631-1636
29. P.D. Boucher et al. Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapy Gene Ther. 9 2002 1023-1030
30. S.B. Kaye Gemcitabine: Current status of phase I and II trials J. Clin. Oncol. 12 1994 1527-1531
31. A.W. Blackstock et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer J. Clin. Oncol. 17 1999 2208-2212
32. A. Eisbruch et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study J. Clin. Oncol. 19 2001 792-799
33. V. Heinemann et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine Mol. Pharmacol. 38 1990 567-572
34. C.H. Baker et al. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase J. Med. Chem. 34 1991 1879-1884
35. L.J. Ostruszka and D.S. Shewach The role of cell cycle progression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine Cancer Res. 60 2000 6080-6088
36. T.S. Lawrence E.Y. Chang T.M. Hahn L.W. Hertel and D.S. Shewach Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine Int. J. Radiat. Oncol. Biol. Phys. 34 1996 867-872
37. D.S. Shewach T.M. Hahn E. Chang L.W. Hertel and T.S. Lawrence Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells Cancer Res. 54 1994 3218-3223
38. L.J. Ostruszka and D.S. Shewach The role of DNA synthesis inhibition in the cytotoxicity of 2′,2′-difluoro-2′-deoxycytidine Cancer Chemother. Pharmacol. 52 2003 325-332
39. V.W.T. Ruiz van Haperen G. Veerman J.B. Vermorken and G.J. Peters 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumor cell lines Biochem. Pharmacol. 46 1993 762-766
40. S.G. Machado and G.A. Robinson A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments Stat. Med. 13 1994 2289-2309
41. J. Qiao M. Black and M. Caruso Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying herpes simplex virus thymidine kinase gene mutant Hum. Gene Ther. 11 2000 1569-1576
42. M.S. Dilber et al. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22 Gene Ther. 6 1999 12-21
43. R. Ramesh A.J. Marrogi A. Munshi and S.M. Freeman Potentiation of the bystander effect by immunization combined with suicide gene therapy Gene Therapy of Cancer 1998 Plenum New York 125-131
44. M. Mesnil C. Piccoli G. Tiraby K. Willecke and H. Yamasaki Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins Proc. Natl. Acad. Sci. USA 93 1996 1831-1835
45. A.A. Elshami et al. Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro Gene Ther. 3 1996 85-92
46. M. Aghi C.M. Kramm T. Chou X.O. Breakefield and E.A. Chiocca Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/ cytosine deaminase gene therapies J. Natl. Cancer Inst. 90 1998 370-380
47. O.M. Wildner R.M. Blaese and F. Candotti Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus cellular thymidine kinase/ ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer Cancer Res. 59 1999 5233-5238
48. R.C. Donehower Hydroxyurea In B.A. Chabner and D.L. Longo (Eds.), Cancer Chemotherapy and Biotherapy 1996 Lippincott-Raven Philadelphia 253-261